Evidence map›Paper›PMID 30447301›Full record

ArticleHuman pathology2019

Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.

Doreen N Palsgrove, Diana Taheri, Simeon U Springer, Morgan Cowan, Gunes Guner, Maria A Mendoza Rodriguez, Maria Del Carmen Rodriguez Pena, Yuxuan Wang, Isaac Kinde, Bernardo F P Ricardo and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Molecular Pathology of Urothelial Carcinoma.Surgical pathology clinics · 2021
    Review
  12. Review
  13. Human TERT promoter mutations as a prognostic biomarker in glioma.Journal of cancer research and clinical oncology · 2021
    Review
  14. Review
  15. Clinical Application ofFrontiers in oncology · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Mutational Landscape and Environmental Effects in Bladder Cancer.International journal of molecular sciences · 2020
    Review
  20. Activating TelomeraseInternational journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Doreen N PalsgroveDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Diana TaheriDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Pathology, Isfahan University of Medical Sciences, Isfahan Kidney Diseases Research Center, Isfahan 81746 73461, Iran.
Simeon U SpringerDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
Morgan CowanDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Gunes GunerDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Maria A Mendoza RodriguezDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Maria Del Carmen Rodriguez PenaDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35249, USA.
Yuxuan WangThe Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
Isaac KindeThe Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
Bernardo F P RicardoDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Isabela CunhaDepartment of Pathology, Rede D'OR São Luiz, São Paulo 03313-000, Brazil.
Kazutoshi FujitaDepartment of Urology, Osaka University, Osaka 565-0871, Japan.
Dilek ErtoyDepartment of Pathology, Koç University, İstanbul 34450, Turkey.
Kenneth W KinzlerDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
Trinity J BivalacquaDepartment of Urology, Johns Hopkins University, Baltimore, MD 21287, USA.
Nickolas PapadopoulosDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
Bert VogelsteinDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
George J NettoDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35249, USA. Electronic address: gnetto@uabmc.edu.

Funding

Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
NCI NIH HHS T32 CA193145
6 · The paper itself

Abstract

Activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the most common genetic alterations in urothelial carcinoma (UC) of the bladder and upper urinary tract. Although the cadherin 1 (CDH1) gene is commonly mutated in the clinically aggressive plasmacytoid variant of urothelial carcinoma (PUC), little is known about their TERT promoter mutation status. A retrospective search of our archives for PUC and UC with plasmacytoid and/or signet ring cell features (2007-2014) was performed. Ten specimens from 10 patients had archived material available for DNA analysis and were included in the study. Intratumoral areas of nonplasmacytoid histology were also evaluated when present. Samples were analyzed for TERT promoter mutations with Safe-SeqS, a sequencing error-reduction technology, and sequenced using a targeted panel of the 10 most commonly mutated genes in bladder cancer on the Illumina MiSeq platform. TERT promoter mutations were detected in specimens with pure and focal plasmacytoid features (6/10). Similar to conventional UC, the predominant mutation identified was g.1295228C>T. In heterogeneous tumors with focal variant histology, concordant mutations were found in plasmacytoid and corresponding conventional, glandular, or sarcomatoid areas. Co-occurring mutations in tumor protein p53 (TP53, 2 cases) and kirsten rat sarcoma (KRAS) viral proto-oncogene (1 case) were also detected. TERT promoter mutations are frequently present in PUC, which provides further evidence that TERT promoter mutations are common events in bladder cancer, regardless of histologic subtype, and supports their inclusion in any liquid biopsy assay for bladder cancer.

Indexed as

MutationPromoter Regions, GeneticAgedAged, 80 and overCarcinoma, Transitional CellFemaleHumansMaleMiddle AgedMutation RateProto-Oncogene MasRetrospective StudiesTelomeraseUrologic NeoplasmsUrotheliumMAS1 protein, humanProto-Oncogene MasTelomeraseTERT protein, humanMutationPlasmacytoidPUCTelomerase reverse transcriptaseTERTUrothelial carcinoma

Identifiers

PMID30447301
PMCPMC6728909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.